In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $54.00. The company’s shares closed last Tuesday at $46.95, close to its 52-week high of
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Chiasma (CHMA – Research Report) on December 1 and set a price target of $10.00. The company’s shares closed last Thursday at $4.21. According to TipRanks.com, Tsao is a 4-star
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Radius Health (RDUS – Research Report), Seres Therapeutics (MCRB – Research Report) and NeuroBo Pharmaceuticals (NRBO – Research Report). Radius Health (RDUS) In a report
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Arena Pharma (ARNA – Research Report) and Avadel Pharmaceuticals (AVDL – Research Report). Alkermes (ALKS) H.C. Wainwright analyst
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crinetics Pharmaceuticals (CRNX – Research Report), Aerie Pharma (AERI – Research Report) and GlycoMimetics (GLYC – Research Report) with bullish sentiments. Crinetics
H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on Argenx Se (ARGX – Research Report) today and set a price target of $265.00. The company’s shares closed last Thursday at $252.24. According to TipRanks.com, Tsao is a 5-star analyst